Case Summary:

An EB2-NIW (National Interest Waiver) case was won for a research fellow in biomedical engineering from Egypt. This was made possible by our team’s diligent work on her petition writing, which included some of the following details:

• An expert in the field of biomedical engineering, the client’s proposed endeavor is to continue to leverage her expertise in biomaterials and regenerative tissue engineering to curate novel treatment methods that are minimally harmful and effective for clinical use.
• Her research is of great value because it helps to treat cancer while reducing the harmful side effects of chemotherapy and addresses common orthopedic injuries.

This is why two of her 4 recommenders had the following to say about her work:

“[The client], through her research on ACL injuries, has created a novel solution to integrate ligament tissue using biomaterials. In effect, she has given athletes a faster, more effective solution for ACL injuries without the risks from autografts and allografts, making [the client] one of the most distinguished modern biomedical engineers.”

“[The client’s] research provides an answer to one of the world’s leading causes of death: cancer. [The client’s] research provides an important molecular drug design to address rising cancer cases. She has developed a more advanced method to administer chemotherapeutic drugs to cancer patients, avoiding many of the unpleasant and often lethal side effects of traditional chemotherapy. Therefore, she has undeniably advanced global health and the biomedical engineering field through her drug research.”

• Her proposed endeavor also has broad implications for the United States since her research promotes orthopedic wound healing and the health of athletes in addition to helping to improve arthritis treatments.
• Her research has resulted in 3 peer-reviewed journal articles (1 of them first-authored) and 1 conference paper. These publications have also been cited 60 times already by researchers all over the world.
• She has pursued research directly related to her proposed endeavor of leveraging her expertise in biomaterials and regenerative tissue engineering for 7 years, which has given her the necessary expertise to continue her work here in the U.S.
• We were also able to gather evidence of her major funding source namely the National Institutes of Health.

Due to the inherent value of her work, another one of her recommenders said:

“Because of the large ACL injury incidence in the United States, [the client’s] research is essential for American athletes and sports teams to thrive after injury. Her research has opened the doors for safer, more efficient treatment methods for ACL injuries, advancing modern medicine and the biomedical engineering field as a whole. Given the significance of her work for American healthcare, the United States would be remiss to disrupt her critical biomedical engineering research.”

These details helped us prove beyond reasonable doubt that she was an excellent researcher and that her work in biomedical engineering was of benefit to the U.S. We are glad to have worked with her and we wish her the best of luck.